Skip to main content
Syschem (India) Ltd. logo

Syschem (India) Ltd. — Investor Relations & Filings

Ticker · 531173 ISIN · INE121D01036 LEI · 8945008RSNJUC3BIID69 BSE.NS Manufacturing
Open in API
Filings indexed 2 across all filing types
Latest filing 2026-05-25 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 531173

About Syschem (India) Ltd.

https://www.syschem.in/

Syschem (India) Ltd. specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. The company focuses on the production of bulk drugs, with a significant emphasis on antibiotic derivatives such as Amoxycillin Trihydrate, Ampicillin Trihydrate, Cloxacillin Sodium, and Dicloxacillin Sodium. Its operations encompass contract manufacturing and custom synthesis, supported by research and development initiatives aimed at process optimization and quality enhancement. The company utilizes advanced chemical synthesis techniques to produce high-quality medicinal components for various therapeutic applications. By maintaining rigorous manufacturing standards, the organization provides essential chemical building blocks and finished bulk drugs to global markets, catering to the requirements of the generic pharmaceutical sector.

Recent filings

Filing Released Lang Actions
Outcome of board meeting results for the quarter and year ending 31st March, 2026
Interim / Quarterly Report Classification · 87% confidence The document is a detailed board meeting outcome filing under SEBI LODR Reg. 33, containing the full audited standalone financial results for the quarter and year ended March 31, 2026, along with the Independent Auditor’s Report and detailed financial tables. It is not merely a brief highlights release (ER), nor is it the full corporate annual report (10-K). It includes actual financial statements for a period shorter than a full fiscal year (quarterly results) and the year‐to‐date figures, and thus qualifies as an Interim/Quarterly Report rather than a simple publication announcement or compliance notice. Therefore, the correct classification is an Interim / Quarterly Report (IR). FY 2026
2026-05-25 English
Outcome of Board meeting dated 25th May, 2026: Audited results for the quarter and year ended 31st March, 2026.
Regulatory Filings Classification · 82% confidence The document is a lengthy stock‐exchange filing under SEBI LODR Regulations 30 and 33 detailing the Outcome of the Board Meeting, approval of the audited financial results, auditor’s report, appointment of auditors, and related annexures. Although it contains financial tables and an auditor’s report, it is primarily a regulatory compliance disclosure rather than a standalone annual report, investor presentation, or formal earnings‐only press release. It does not fit cleanly into Interim/Quarterly Report (IR), Earnings Release (ER), Audit Report only (AR), or any other specific category, so it falls into the fallback “General Regulatory Filings” category (RNS).
2026-05-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.